NEJM· @NEJM · X·· 28 天前精选AI 评分62
AI 导读
NEJM发布ANTHEM-UC 2期试验结果,每日一次口服icotrokinra用于中重度活动性溃疡性结肠炎,三个测试剂量组第12周临床缓解率均高于安慰剂。完整结果与研究摘要见链接。
推荐理由
2期试验显示口服icotrokinra三个剂量组第12周临床缓解率均高于安慰剂,可供观察口服方案在溃疡性结肠炎中的位置。
正文
In a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo. Full ANTHEM-UC trial results and Research Summary: https://nej.md/4hLHjhO
来源:NEJM · x.com